Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Fragile X syndrome: from molecular genetics to therapy.

D'Hulst C, Kooy RF.

J Med Genet. 2009 Sep;46(9):577-84. doi: 10.1136/jmg.2008.064667. Review.

PMID:
19724010
2.

The fragile X syndrome: exploring its molecular basis and seeking a treatment.

Bardoni B, Davidovic L, Bensaid M, Khandjian EW.

Expert Rev Mol Med. 2006 Apr 21;8(8):1-16. Review.

PMID:
16626504
3.

Fragile X syndrome: From protein function to therapy.

Bagni C, Oostra BA.

Am J Med Genet A. 2013 Nov;161A(11):2809-21. doi: 10.1002/ajmg.a.36241. Epub 2013 Sep 24. Review.

PMID:
24115651
4.

Fragile X mental retardation syndrome: structure of the KH1-KH2 domains of fragile X mental retardation protein.

Valverde R, Pozdnyakova I, Kajander T, Venkatraman J, Regan L.

Structure. 2007 Sep;15(9):1090-8.

5.

[Experimental therapeutic models for fragile X syndrome].

de Diego-Otero Y.

Rev Neurol. 2001 Oct;33 Suppl 1:S70-6. Spanish.

6.

Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.

Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST.

Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15537-42. Epub 2007 Sep 19.

7.

Fragile X mental retardation protein: past, present and future.

Kim M, Ceman S.

Curr Protein Pept Sci. 2012 Jun;13(4):358-71. Review.

PMID:
22708486
8.

Molecular diagnosis of Fragile X syndrome.

Sofocleous C, Kolialexi A, Mavrou A.

Expert Rev Mol Diagn. 2009 Jan;9(1):23-30. doi: 10.1586/14737159.9.1.23.

PMID:
19099346
9.

Advances in understanding fragile X syndrome and related disorders.

Rooms L, Kooy RF.

Curr Opin Pediatr. 2011 Dec;23(6):601-6. doi: 10.1097/MOP.0b013e32834c7f1a. Review.

PMID:
22001764
10.

Understanding the biological underpinnings of fragile X syndrome.

Chiurazzi P, Neri G, Oostra BA.

Curr Opin Pediatr. 2003 Dec;15(6):559-66. Review.

PMID:
14631199
11.

Molecular phenotype of Fragile X syndrome: FMRP, FXRPs, and protein targets.

Kaufmann WE, Cohen S, Sun HT, Ho G.

Microsc Res Tech. 2002 May 1;57(3):135-44. Review.

PMID:
12112448
12.

Tdrd3 is a novel stress granule-associated protein interacting with the Fragile-X syndrome protein FMRP.

Linder B, Plöttner O, Kroiss M, Hartmann E, Laggerbauer B, Meister G, Keidel E, Fischer U.

Hum Mol Genet. 2008 Oct 15;17(20):3236-46. doi: 10.1093/hmg/ddn219. Epub 2008 Jul 28.

PMID:
18664458
13.

Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome.

Koukoui SD, Chaudhuri A.

Brain Res Rev. 2007 Jan;53(1):27-38. Epub 2006 Jul 17. Review.

PMID:
16844227
14.

Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome.

Romero-Zerbo Y, Decara J, el Bekay R, Sanchez-Salido L, Del Arco-Herrera I, de Fonseca FR, de Diego-Otero Y.

J Pineal Res. 2009 Mar;46(2):224-34. doi: 10.1111/j.1600-079X.2008.00653.x. Epub 2008 Dec 23.

PMID:
19141086
15.

The fragile X syndrome: from molecular genetics to neurobiology.

Willemsen R, Oostra BA, Bassell GJ, Dictenberg J.

Ment Retard Dev Disabil Res Rev. 2004;10(1):60-7. Review.

PMID:
14994290
16.

[Experimental therapy: reactivation of the FMR1 gene involved in fragile X syndrome].

Chiurazzi P, Neri G.

Rev Neurol. 2001 Oct;33 Suppl 1:S62-5. Spanish.

17.
18.

Lessons from fragile X regarding neurobiology, autism, and neurodegeneration.

Hagerman RJ.

J Dev Behav Pediatr. 2006 Feb;27(1):63-74. Review.

PMID:
16511373
19.
20.

Supplemental Content

Support Center